摘要
Dapagliflozin在治疗2型糖尿病的临床前期和临床期研究表明,钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂增加肾糖排泄,可以降低血糖以及减轻体质量。大型试验论证了Dapagliflozin可能产生良好的效果而不出现重大不良反应,说明其具有安全性和有效性。因此,这类药物具有超过目前使用的许多降糖药的优势。现就SGLT2在糖代谢方面的作用和目前Dapagliflozin在治疗糖尿病中的应用进行综述。
Preclinical and clinical studies of dapagliflozin in subjects with type 2 diabetes reveal that increasing renal glucose excretion by sodium-glucose cotransporter 2（SGLT2）inhibitor can lower plasma glucose levels,as well as reduce body weight.Further data from larger trials are forthcoming regarding efficacy and safety,but the results reported thus far suggest that the positive impact of SGLT2 inhibitors may be attained without producing significant adverse effects.This class of agents may thus hold an advantage over many currently used medications for diabetes.This review outlines the role of SGLT2 in glucose homeostasis and the evidence currently available on the potential for clinical application of dapagliflozin in diabetes.
出处
《医学综述》
2012年第1期133-136,共4页
Medical Recapitulate
